VCBeat Health
Contact Us
Home
China Healthcare Select
Insights
MNC China Lens
Vertical Industries
Services
About VCBeat
Why VCBeat
Log In
Home
Hengrui Pharma's HRS-1635 Tablets Receive Clinical Trial Approval from China's NMPA for B-cell Malignancies
Hengrui Pharma's HRS-1635 Tablets Receive Clinical Trial Approval from China's NMPA for B-cell Malignancies
May 26, 2026 16:49 CST Updated 18:28
Share:
Hengrui Pharma
Innovative and High-Quality Pharmaceutical Developer